Those include Radiology Partners, Solis Mammography, Cleveland Clinic, Stanford Health Care and Intermountain, among others, the college announced Thursday.
Non-white individuals and people living in less educated, lower income areas are more likely to receive an advanced lung cancer diagnosis, such as stage 4 disease.
“I am concerned by the FDA’s slow action, over multiple administrations, to protect patients from this product despite early warning signs,” one U.S. representative said in an open letter.